Welch & Forbes LLC Sells 1,388 Shares of Thermo Fisher Scientific Inc. $TMO

Welch & Forbes LLC reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 89,726 shares of the medical research company’s stock after selling 1,388 shares during the period. Welch & Forbes LLC’s holdings in Thermo Fisher Scientific were worth $43,519,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Town & Country Bank & Trust CO dba First Bankers Trust CO increased its position in Thermo Fisher Scientific by 91.9% during the third quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO now owns 4,872 shares of the medical research company’s stock valued at $2,363,000 after acquiring an additional 2,333 shares during the last quarter. Argent Advisors Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 3rd quarter valued at about $274,000. Meridian Management Co. lifted its stake in shares of Thermo Fisher Scientific by 2.0% in the 3rd quarter. Meridian Management Co. now owns 10,373 shares of the medical research company’s stock worth $5,031,000 after purchasing an additional 207 shares during the period. Everett Harris & Co. CA boosted its holdings in shares of Thermo Fisher Scientific by 0.5% in the third quarter. Everett Harris & Co. CA now owns 15,531 shares of the medical research company’s stock worth $7,533,000 after buying an additional 76 shares during the last quarter. Finally, IFC Advisors LLC increased its holdings in Thermo Fisher Scientific by 2.1% during the third quarter. IFC Advisors LLC now owns 3,254 shares of the medical research company’s stock valued at $1,578,000 after buying an additional 67 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Trending Headlines about Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q4 results beat expectations — Adjusted EPS $6.57 and revenue $12.21B (≈+7% YoY), driven by life-sciences tools and pharma demand; the print supports near-term organic growth narrative. Read More.
• Positive Sentiment: Analyst support remains — several firms reiterated buys/positive views and one bullish write-up called the pullback a buying opportunity, highlighting resilient margins and competitive positioning. Read More.
• Neutral Sentiment: 2026 guidance set in a narrow band — FY26 revenue guide $46.3B–$47.2B and EPS $24.22–$24.80, roughly around consensus but slightly below EPS midpoint; guidance implies modest 3%–4% organic growth and stabilizing demand. Read More.
• Negative Sentiment: Market reaction focused on cautious profit outlook and margin pressure — despite the beat, investors sold into the print due to conservative margin commentary and a guidance range that doesn’t accelerate growth significantly. Read More.
• Negative Sentiment: Analyst price-target trim — TD Cowen lowered its PT from $696 to $683 while keeping a Buy rating, signaling slightly reduced upside expectations even as coverage stays positive. Read More.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Michel Lagarde sold 22,046 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $563.56, for a total transaction of $12,424,243.76. Following the sale, the chief operating officer directly owned 84,117 shares in the company, valued at approximately $47,404,976.52. This represents a 20.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael D. Shafer sold 10,725 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total value of $6,435,000.00. Following the completion of the transaction, the executive vice president owned 18,731 shares of the company’s stock, valued at approximately $11,238,600. This represents a 36.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 124,517 shares of company stock worth $72,363,568. Company insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the subject of a number of recent research reports. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Friday, January 9th. Evercore ISI reissued an “outperform” rating and set a $650.00 price target on shares of Thermo Fisher Scientific in a report on Monday, January 5th. Stifel Nicolaus raised their price objective on Thermo Fisher Scientific from $583.00 to $700.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. The Goldman Sachs Group started coverage on Thermo Fisher Scientific in a research note on Tuesday, December 9th. They set a “buy” rating and a $685.00 price objective for the company. Finally, Citigroup raised their target price on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a “buy” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $633.68.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $578.20 on Friday. The firm’s fifty day moving average is $593.96 and its two-hundred day moving average is $537.07. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99. The company has a market cap of $217.24 billion, a P/E ratio of 32.59, a P/E/G ratio of 3.89 and a beta of 0.91. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.11 and a current ratio of 1.89.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.45 by $0.12. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The firm had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.95 billion. During the same period in the previous year, the firm posted $6.10 earnings per share. The business’s revenue was up 7.2% compared to the same quarter last year. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its board has authorized a stock buyback plan on Thursday, November 6th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, January 15th. Stockholders of record on Monday, December 15th were given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date was Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.94%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.